Financial markets in 2025 are defined by caution. From equities to commodities, investors are weighing every position more carefully amid slowing growth, trade tensions and a global reset in interest rate expectations. The risk-off tone has pushed capital into perceived safe havens — yet biotechnology, long known as one of the market’s most volatile sectors, continues to command attention.
The question is whether biotech can still thrive as a destination for capital when risk aversion is the prevailing mood.
According to Cruz Li, head of marketing at Tiger Brokers Australia, the answer depends on how investors frame both the risks and the rewards.
“In risk-averse markets, biotech stands out for its innovation and potential to address vital healthcare needs, including innovations that aim to cure diseases which medicine hasn’t fully solved yet and transformative solutions like new cures and sustainable alternatives,” Li explained.
“However, it is particularly vulnerable due to long development cycles, regulatory hurdles and dependence on funding,” he added. “Investors typically shift capital away from early-stage and riskier biotech enterprises toward more mature, clinically validated projects.”
A sector built on innovation and uncertainty
Biotech’s core appeal lies in its ambition to solve medicine’s hardest problems — from cancer and neurodegenerative diseases to infectious threats that can upend global economies. Innovations such as gene therapies, targeted oncology drugs and sustainable biomaterials represent genuine opportunities for outsized growth.
Yet these same strengths also expose the sector to heightened risk. Even the most promising therapies can stall before reaching market, and setbacks — from policy changes to adverse trial data — can erase billions in value overnight. Ethical questions around technologies like gene editing add further complexity.
“Compared to more established sectors, biotech faces amplified risks from scientific uncertainty and policy changes, as well as significant ethical debates,” Li noted. “It is more sensitive to shifts in market sentiment than most industries.”
That blend of innovation and vulnerability means biotech demands a more selective, disciplined approach from investors.
Capital constraints and the valuation squeeze
Global monetary tightening has left a clear mark on biotech. As liquidity dries up, the sector’s traditional dependence on capital markets has become a liability.
“Tighter capital markets and higher rates have depressed biotech valuations, increasing funding costs and making capital scarcer, especially for early-stage companies,” said Li.
That pressure has widened the gap between early and later-stage firms. Investors now favour companies with proven trial data or commercial products, while pre-clinical ventures face tougher funding conditions and longer scrutiny.
“When weighing opportunities, investors should consider that early-stage companies offer high upside but face amplified risk and funding headwinds, whereas later-stage companies may provide more stability but potentially less dramatic returns,” Li said.
The result is a flight to maturity: capital concentrating around advanced programs and revenue-generating businesses, while early innovators wait for sentiment — and funding appetite — to recover.
Biotech as a defensive play
Despite its reputation for volatility, biotech also carries features that can appeal to defensive-minded investors. Demand for healthcare is remarkably inelastic: patients need treatments regardless of macroeconomic cycles, and governments consistently support critical therapies through subsidies, reimbursement and emergency authorisations.
“Biotech can play a defensive role in portfolios during uncertain times because healthcare demand remains stable, and life-saving therapies are always needed,” Li said. “The biotech sector is generally considered less sensitive during economic downturns, as its products are essential and less dependent on overall economic conditions.”
Alliances with major players further strengthen resilience. Large pharmaceutical companies increasingly rely on biotech innovators to fill their pipelines, providing funding, technical expertise and distribution clout in return for access to cutting-edge science.
“Strategic partnerships with big pharma enhance resilience by providing funding, expertise and greater chances of regulatory success for biotech innovations,” Li noted. “However, not all biotechs are equally defensive, so investors should prioritise established firms or those with strong pharma alliances for greater downside protection.”
He added that policy support also plays a role in cushioning the sector. Support from governments and regulators, combined with biotech’s critical role in public health crises, can reinforce its stability.
“Focusing investments on biotech companies that develop solutions for fundamental health needs or provide essential medical services, such as cancer therapies or infectious disease vaccines, can offer a stronger defensive advantage,” Li said.
Catalysts in a cautious market
Even in risk-averse times, certain themes continue to attract capital to biotech, and new technological catalysts are reshaping where investors look for opportunity.
“While oncology remains a critical focus, the integration of AI provides a more efficient pathway for innovation both within this field and beyond,” Li said. “AI drug discovery remains the theme most likely to attract investment, as it directly addresses the high costs and failure rates of traditional drug development by accelerating target identification, optimising drug efficacy and increasing the likelihood of success for novel therapies, particularly in oncology.”
That intersection of biotech and artificial intelligence has become one of the sector’s brightest spots — drawing interest from both venture and institutional investors eager to shorten development timelines and reduce costs. Meanwhile, regulatory tailwinds, such as faster approval pathways for rare diseases and orphan drugs, continue to support targeted innovation even when broader market sentiment is cautious.
“Regulatory shifts can act as catalysts for change,” Li added, “but are unlikely to draw investment on their own.”
Managing risk and finding opportunity
For investors, biotech’s appeal lies in its ability to combine meaningful impact with potential outperformance — but understanding where that opportunity sits in the development cycle is critical.
“Retail investors should carefully weigh the high potential rewards of individual biotech companies against the sector’s inherent volatility and long development timelines, focusing on firms with strong pipelines, strategic partnerships and clear commercialisation paths,” according to Li.
At the same time, the technical and regulatory complexity of biotech means that discipline and diversification matter.
“Key risks mainly stem from technology and R&D, so investors should closely assess technical feasibility, clinical trial outcomes, and pipeline maturity, while also considering regulatory compliance, market competition and liquidity,” Li said.
“We emphasise balancing these individual company stories with broader sector trends and policy support… as well as regulatory shifts, while diversifying across companies at different stages, therapeutic areas, and technology platforms to build a resilient portfolio in uncertain markets,” he added.
Selective optimism
Biotech’s long timelines and capital intensity make it a challenging sector in the best of times, let alone when markets are risk-averse. Yet its role in driving medical progress — and its capacity to generate breakthrough value — keep it firmly on investors’ radars.
In a market defined by caution, the most successful biotech investors may be those who approach the sector not as a gamble, but as a series of calculated bets: identifying where science meets scalability, and where strategic partnerships turn potential into tangible growth.